Danske: Sanofi announcement is a big deal
According to Danske Capital, it caused quite a stir in the market when Sanofi reported stagnating growth on the US market
BY STEFAN SINGH KAILAY
One of the major events in the global life science industry last month was a surprise announcement from French drug group Sanofi growth in the sale of its cash cow, the highest-grossing diabetes drug in the world, Lantus, was slowing down.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo examines once-weekly insulin
For abonnenter
“Novo can say what they want to”
For abonnenter
